Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).
Fiche publication
Date publication
juin 2019
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme, Pr MANFREDI Sylvain
Tous les auteurs :
Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V, Cowen D, Lepage C, Aparicio T,
Lien Pubmed
Résumé
Standard treatment of epidermoid anal cancer is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT). This phase I study aims to evaluate the addition of panitumumab (Pmab) to CRT and to determine the maximum tolerated dose (MTD) of Pmab and 5-FU in combination with CRT.
Mots clés
Anal cancer, Chemoradiotherapy, Epidermal growth factor receptor, Immunotherapy, Panitumumab, Squamous cell carcinoma
Référence
Radiother Oncol. 2019 Jun 8;140:84-89